EUVIMEDEUVIMED entdecken
Multizentrische StudieRandomisierte kontrollierte Studie

Home Treatment for Active Cancer Patients With Low-Risk Pulmonary Embolism ― A Predetermined Companion Report From the ONCO PE Trial ―

Ryuki Chatani, Yugo Yamashita, Takeshi Morimoto, Nao Muraoka, Wataru Shioyama, Tatsuhiro Shibata, Yuji Nishimoto, Yoshito Ogihara, Kosuke Doi, Maki Oi, Taro Shiga, Daisuke Sueta und 23 weitere

Circulation Journal · 2024

DOI: 10.1253/circj.cj-24-0004 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Circulation Journal, 2024. Verfasst von Ryuki Chatani und 34 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiovascular Medicine, Kurashiki Central Hospital. Hauptthemen laut MEDLINE: Pulmonary Embolism, Neoplasms, Rivaroxaban, Home Care Services. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 22 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Patients with appropriately selected low-risk pulmonary embolism (PE) can be treated at home, although it has been controversial whether applies to patients with cancer, who are considered not to be at low risk.Methods and Results: The current predetermined companion report from the ONCO PE trial evaluated the 3-month clinical outcomes of patients with home treatment and those with in-hospital treatment. The ONCO PE trial was a multicenter, randomized clinical trial among 32 institutions in Japan investigating the optimal duration of rivaroxaban treatment in cancer-associated PE patients with a score of 1 using the simplified version of the Pulmonary Embolism Severity Index (sPESI). Among 178 study patients, there were 66 (37%) in the home treatment group and 112 (63%) in the in-hospital treatment group. The primary endpoint of a composite of PE-related death, recurrent venous thromboembolism (VTE) and major bleeding occurred in 3 patients (4.6% [0.0-9.6%]) in the home treatment group and in 2 patients (1.8% [0.0-4.3%]) in the in-hospital treatment group. In the home treatment group, there were no cases of PE-related death or recurrent VTE, but major bleeding occurred in 3 patients (4.6% [0.0-9.6%]), and 2 patients (3.0% [0.0-7.2%]) required hospitalization due to bleeding events. CONCLUSIONS: Active cancer patients with PE of sPESI score=1 could be potential candidates for home treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pulmonary EmbolismNeoplasmsRivaroxabanHome Care ServicesFactor Xa InhibitorsHumansMaleFemaleAgedMiddle AgedJapanHemorrhageTreatment OutcomeRisk FactorsAged, 80 and overVenous Thromboembolism

Stichwörter der Autor:innen

AnticoagulantsCancerCardio-oncologyHome treatmentPulmonary embolism

Substanzen

RivaroxabanFactor Xa Inhibitors

Autor:innen und Institutionen

  • Department of Cardiovascular Medicine, Kurashiki Central Hospital.
  • Department of Cardiovascular Medicine, Graduate School of Medicine, Kyoto University.
  • Department of Clinical Epidemiology, Hyogo Medical University.
  • Division of Cardiology, Shizuoka Cancer Center.
  • Department of Cardiovascular Medicine, Shiga University of Medical Science.
  • Division of Cardiovascular Medicine, Department of Internal Medicine, Kurume University School of Medicine.

Zitieren

APA

Chatani, R., Yamashita, Y., Morimoto, T., Muraoka, N., Shioyama, W., Shibata, T., Nishimoto, Y., Ogihara, Y., Doi, K., Oi, M., Shiga, T., Sueta, D., Kim, K., Tanabe, Y., Koitabashi, N., Takada, T., Ikeda, S., Nakagawa, H., Mitsuhashi, T., …, & ONCO PE Trial Investigators (2024). Home Treatment for Active Cancer Patients With Low-Risk Pulmonary Embolism ― A Predetermined Companion Report From the ONCO PE Trial ―. Circulation Journal. https://doi.org/10.1253/circj.cj-24-0004

Vancouver

Chatani R, Yamashita Y, Morimoto T, Muraoka N, Shioyama W, Shibata T, et al. Home Treatment for Active Cancer Patients With Low-Risk Pulmonary Embolism ― A Predetermined Companion Report From the ONCO PE Trial ―. Circulation Journal. 2024. doi:10.1253/circj.cj-24-0004

BibTeX
@article{Chatani2024,
  author = {Chatani, Ryuki and Yamashita, Yugo and Morimoto, Takeshi and Muraoka, Nao and Shioyama, Wataru and Shibata, Tatsuhiro and Nishimoto, Yuji and Ogihara, Yoshito and Doi, Kosuke and Oi, Maki and Shiga, Taro and Sueta, Daisuke and Kim, Kitae and Tanabe, Yasuhiro and Koitabashi, Norimichi and Takada, Takuma and Ikeda, Satoshi and Nakagawa, Hitoshi and Mitsuhashi, Takayuki and Shoji, Masaaki and Sakamoto, Jiro and Hisatake, Shinji and Ogino, Yutaka and Fujita, Masashi and Nakanishi, Naohiko and Dohke, Tomohiro and Hiramori, Seiichi and Nawada, Ryuzo and Kaneda, Kazuhisa and Mushiake, Kazunori and Yamamoto, Hiromi and Kadota, Kazushige and Ono, Koh and Kimura, Takeshi and ONCO PE Trial Investigators, ONCO PE Trial Investigators},
  title = {Home Treatment for Active Cancer Patients With Low-Risk Pulmonary Embolism ― A Predetermined Companion Report From the ONCO PE Trial ―},
  journal = {Circulation Journal},
  year = {2024},
  doi = {10.1253/circj.cj-24-0004}
}
Kostenlos starten →